I agree. It seems to me management will have the choice between the same two options it did months ago. The first is to wait until it signs a commercial deal for one of its existing products, which could take well into next year unless a big licencing agreement is reached for an existing product (Permatrex). The second is to conduct another CR and get these products to phase 2 ASAP.
Personally, I can see the advantages of getting these products through the pipeline as soon as possible. A CR before the share price breaks pending successful phase two results isn't the end of the world if you are in this for the long-term.
Ann: Preliminary Final Report, page-12
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.005(1.47%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 33.3¢ | $538.2K | 1.596M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 152563 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 242043 | 17 |
View Market Depth
| Last trade - 12.37pm 04/12/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
